Korean J Ophthalmol.  2012 Feb;26(1):26-31. 10.3341/kjo.2012.26.1.26.

The Efficacy of a Monocular Drug Trial in Normal-Tension Glaucoma

• Lee JY
• Hwang YH
• Kim YY

• KMID: 1120178
• DOI: http://doi.org/10.3341/kjo.2012.26.1.26

Abstract

PURPOSE
To evaluate the efficacy of a monocular drug trial in eyes with normal-tension glaucoma (NTG).
METHODS
This prospective study enrolled 74 patients with NTG. The monocular drug trial was started using latanoprost 0.005% for one week. If the intraocular pressure (IOP) reduction was greater than 15%, the same medication was administered to both eyes for one month. The unadjusted change and adjusted change (the change in the treated eye minus the change in the contralateral eye) in IOP were evaluated, and the predictors of IOP response were analyzed by multivariate linear regression.
RESULTS
Among the initial 74 patients, 31 (41.9%) were included; others were excluded because they did not meet the requisite conditions. The most significant predictors of IOP response in the initial eye and subsequent eye were the baseline IOPs in both eyes (beta = 0.907, 0.771, respectively). The adjusted change in IOP of the initial eye had greater association (beta = 0.589) with the IOP after monocular trial in the initial eye than that of unadjusted IOP change (beta = 0.279). The adjusted change in IOP also had greater predictability (beta = 0.348) for IOP after monocular trial in the subsequent eye than that of the unadjusted IOP change (beta = 0.090).
CONCLUSIONS
Although the monocular trial in NTG patients had limited efficacy due to its stringent conditions, it was useful for evaluating the IOP response in the initial eye and for predicting the IOP response in the subsequent eye.

Keyword

Latanoprost; Low tension glaucoma; Monocular drug trial; Normal-tension glaucoma

MeSH Terms

Adult
Aged
Aged, 80 and over
Antihypertensive Agents/*therapeutic use
Female
Humans
Intraocular Pressure/drug effects
Linear Models
Low Tension Glaucoma/*drug therapy
Male
Middle Aged
Prospective Studies
Prostaglandins F, Synthetic/*therapeutic use
Statistics, Nonparametric
Treatment Outcome

Reference

1. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002. 120:1268–1279.

2. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998. 126:487–497.

3. Realini T, Fechtner RD, Atreides SP, Gollance S. The uniocular drug trial and second-eye response to glaucoma medications. Ophthalmology. 2004. 111:421–426.

4. Dayanir V, Cakmak H, Berkit I. The one-eye trial and fellow eye response to prostaglandin analogues. Clin Experiment Ophthalmol. 2008. 36:136–141.

5. Shin HH, Yoo CK, Choi YJ, Kim YY. The usefulness of the uniocular drug trial in the glaucoma eyes. J Korean Ophthalmol Soc. 2007. 48:91–96.

6. Chaudhary O, Adelman RA, Shields MB. Predicting response to glaucoma therapy in one eye based on response in the fellow eye: the monocular trial. Arch Ophthalmol. 2008. 126:1216–1220.

7. Takahashi M, Higashide T, Sakurai M, Sugiyama K. Discrepancy of the intraocular pressure response between fellow eyes in one-eye trials versus bilateral treatment: verification with normal subjects. J Glaucoma. 2008. 17:169–174.

8. Leffler CT, Amini L. Interpretation of uniocular and binocular trials of glaucoma medications: an observational case series. BMC Ophthalmol. 2007. 7:17.

9. Realini TD. A prospective, randomized, investigator-masked evaluation of the monocular trial in ocular hypertension or open-angle glaucoma. Ophthalmology. 2009. 116:1237–1242.

10. Iwase A, Suzuki Y, Araie M, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004. 111:1641–1648.

11. Kim CS, Seong GJ, Lee NH, et al. Prevalence of primary open-angle glaucoma in central South Korea the Namil study. Ophthalmology. 2011. 118:1024–1030.

12. Camras CB, Hedman K. US Latanoprost Study Group. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003. 12:466–469.

13. American Academy of Ophthalmology Preferred Practice Pattern Collection. Primary open-angle glaucoma. 2003. San Francisco: American Academy of Ophthlamology.

14. Smith J, Wandel T. Rationale for the one-eye therapeutic trial. Ann Ophthalmol. 1986. 18:8.

15. Piltz J, Gross R, Shin DH, et al. Contralateral effect of topical beta-adrenergic antagonists in initial one-eyed trials in the ocular hypertension treatment study. Am J Ophthalmol. 2000. 130:441–453.

16. Bhorade AM, Gordon MO, Wilson B, et al. Variability of intraocular pressure measurements in observation participants in the ocular hypertension treatment study. Ophthalmology. 2009. 116:717–724.

17. Leffler CT. Studies of monocular trials of glaucoma medications: conflicting results explained by varying methods. Arch Ophthalmol. 2009. 127:707–708.

18. Maul E, Carrasco FG, Costa VP, et al. A 6-week, multicenter, randomized, double-masked, parallel-group study comparing travoprost 0.004% to latanoprost 0.005% followed by 6-week, open-label treatment with travoprost 0.004%. Clin Ther. 2007. 29:1915–1923.

19. Johnson TV, Fan S, Zhan G, et al. Efficacy and mechanisms of intraocular pressure reduction with latanoprost and timolol in participants with ocular hypertension: a comparison of 1 and 6 weeks of treatment. J Glaucoma. 2010. 19:356–364.